|
1
|
Jacobs IJ and Menon U: Progress and
challenges in screening for early detection of ovarian cancer. Mol
Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nozawa S, Yajima M, Sakuma T, et al:
Cancer-associated galactosyltransferase as a new tumor marker for
ovarian clear cell carcinoma. Cancer Res. 50:754–759.
1990.PubMed/NCBI
|
|
3
|
Haruta S, Furukawa N, Yoshizawa Y, et al:
Molecular genetics and epidemiology of epithelial ovarian cancer
(Review). Oncol Rep. 26:1347–1356. 2011.PubMed/NCBI
|
|
4
|
Gadducci A, Lanfredini N and Tana R: Novel
insights on the malignant transformation of endometriosis into
ovarian carcinoma. Gynecol Endocrinol. 30:612–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue
AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic
features of ovarian cancers: Implications for diagnosis and
treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmed AA, Etemadmoghadam D, Temple J, et
al: Driver mutations in TP53 are ubiquitous in high grade serous
carcinoma of the ovary. J Pathol. 221:49–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uekuri C, Shigetomi H, Ono S, Sasaki Y,
Matsuura M and Kobayashi H: Toward an understanding of the
pathophysiology of clear cell carcinoma of the ovary (Review).
Oncol Lett. 6:1163–1173. 2013.PubMed/NCBI
|
|
8
|
Shimizu M, Nikaido T, Toki T, Shiozawa T
and Fujii S: Clear cell carcinoma has an expression pattern of cell
cycle regulatory molecules that is unique among ovarian
adenocarcinomas. Cancer. 85:669–677. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shigetomi H, Sudo T, Shimada K, et al:
Inhibition of cell death and induction of G2 arrest accumulation in
human ovarian clear cells by HNF-1β transcription factor:
Chemosensitivity is regulated by checkpoint kinase CHK1. Int J
Gynecol Cancer. 24:838–843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shigetomi H, Higashiura Y, Kajihara H and
Kobayashi H: A potential link of oxidative stress and cell cycle
regulation for development of endometriosis. Gynecol Endocrinol.
28:897–902. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gütgemann I, Lehman NL, Jackson PK and
Longacre TA: Emi1 protein accumulation implicates misregulation of
the anaphase promoting complex/cyclosome pathway in ovarian clear
cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Min KW, Park MH, Hong SR, et al:
Gynecologic Pathology Study Group of the Korean Society of
Pathologists. Clear cell carcinomas of the ovary: A
multi-institutional study of 129 cases in Korea with prognostic
significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 32:3–14.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arnason T, Pino MS, Yilmaz O, et al:
Cables1 is a tumor suppressor gene that regulates intestinal tumor
progression in Apc(Min) mice. Cancer Biol Ther. 14:672–678. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin F, Zhang PL, Yang XJ, et al: Human
kidney injury molecule-1 (hKIM-1): A useful immunohistochemical
marker for diagnosing renal cell carcinoma and ovarian clear cell
carcinoma. Am J Surg Pathol. 31:371–381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsuda H, Bandera CA, Birrer MJ, Hashiguchi
Y, Berkowitz RS and Mok SC: Cyclin E amplification and
overexpression in clear cell adenocarcinoma of the ovary. Oncology.
67:291–299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaneuchi M, Sasaki M, Tanaka Y, et al:
Expression and methylation status of 14-3-3 sigma gene can
characterize the different histological features of ovarian cancer.
Biochem Biophys Res Commun. 316:1156–1162. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alkatout I, Friemel J, Sitek B, Anlauf M,
Eisenach PA, Stühler K, Scarpa A, Perren A, Meyer HE, Knoefel WT,
et al: Novel prognostic markers revealed by a proteomic approach
separating benign from malignant insulinomas. Mod Pathol. 28:69–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byrne JA, Maleki S, Hardy JR, et al: MAL2
and tumor protein D52 (TPD52) are frequently overexpressed in
ovarian carcinoma, but differentially associated with histological
subtype and patient outcome. BMC Cancer. 10:4972010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campbell IG, Russell SE, Choong DY, et al:
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer
Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuo KT, Mao TL, Jones S, et al: Frequent
activating mutations of PIK3CA in ovarian clear cell carcinoma. Am
J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamoto S, Tsuda H, Miyai K, Takano M,
Tamai S and Matsubara O: Gene amplification and protein
overexpression of MET are common events in ovarian clear-cell
adenocarcinoma: Their roles in tumor progression and
prognostication of the patient. Mod Pathol. 24:1146–55. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugita S, Morishita Y, Kano J, Furuya S,
Shiba-Ishii A and Noguchi M: IGFBP-1 is expressed specifically in
ovarian clear cell adenocarcinoma. Histopathology. 58:729–738.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Rosen DG, Wang H, Fuller GN, Zhang
W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are
differentially regulated in ovarian cancer of different histologic
types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bell JL, Wächter K, Mühleck B, et al:
Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs):
Post-transcriptional drivers of cancer progression? Cell Mol Life
Sci. 70:2657–2675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boonjaraspinyo S, Boonmars T, Wu Z, et al:
Platelet-derived growth factor may be a potential diagnostic and
prognostic marker for cholangiocarcinoma. Tumour Biol.
33:1785–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto S, Tsuda H, Takano M, et al:
Expression of platelet-derived growth factors and their receptors
in ovarian clear-cell carcinoma and its putative precursors. Mod
Pathol. 21:115–124. 2008.PubMed/NCBI
|
|
27
|
Prentice LM, Klausen C, Kalloger S, et al:
Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients
defines favourable prognosis and clear cell subtype in ovarian
carcinoma. BMC Med. 15:5–33. 2007.
|
|
28
|
Canbay E, Ergen A, Bugra D, et al:
Kisspeptin-54 levels are increased in patients with colorectal
cancer. World J Surg. 36:2218–2224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujimura M, Katsumata N, Tsuda H, et al:
HER2 is frequently over-expressed in ovarian clear cell
adenocarcinoma: Possible novel treatment modality using recombinant
monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res.
93:1250–1257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taniguchi F, Itamochi H, Harada T and
Terakawa N: Fibroblast growth factor receptor 2 expression may be
involved in transformation of ovarian endometrioma to clear cell
carcinoma of the ovary. Int J Gynecol Cancer. 23:791–796. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maretzky T, Le Gall SM, Worpenberg-Pietruk
S, et al: Src stimulates fibroblast growth factor receptor-2
shedding by an ADAM15 splice variant linked to breast cancer.
Cancer Res. 69:4573–4576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W, Wang H, Jin X and Zhao L: Loss of
RhoGDI is a novel independent prognostic factor in hepatocellular
carcinoma. Int J Clin Exp Pathol. 6:2535–2541. 2013.PubMed/NCBI
|
|
33
|
Canet B, Pons C, Espinosa I and Prat J:
Ovarian clear cell carcinomas: RHO GTPases may contribute to
explain their singular biologic behavior. Hum Pathol. 42:833–839.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clayton EF, Ziober A, Yao Y and Bing Z:
Malignant tumors with clear cell morphology: A comparative
immunohistochemical study with renal cell carcinoma antibody, Pax8,
steroidogenic factor 1, and brachyury. Ann Diagn Pathol.
17:192–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsuchiya A, Sakamoto M, Yasuda J, et al:
Expression profiling in ovarian clear cell carcinoma:
Identification of hepatocyte nuclear factor-1 beta as a molecular
marker and a possible molecular target for therapy of ovarian clear
cell carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Senkel S, Lucas B, Klein-Hitpass L and
Ryffel GU: Identification of target genes of the transcription
factor HNF1beta and HNF1alpha in a human embryonic kidney cell
line. Biochim Biophys Acta. 1731:179–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirasawa A, Saito-Ohara F, Inoue J, et al:
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas
with poor prognosis and identification of PPM1D and APPBP2 as
likely amplification targets. Clin Cancer Res. 9:1995–2004.
2003.PubMed/NCBI
|
|
38
|
Liang L, Li Q, Huang LY, Li W, Wang YW, Li
XX and Cai SJ: Loss of ARHGDIA expression is associated with poor
prognosis in HCC and promotes invasion and metastasis of HCC cells.
Int J Oncol. 45:659–666. 2014.PubMed/NCBI
|
|
39
|
Nezhat F, Cohen C, Rahaman J, Gretz H,
Cole P and Kalir T: Comparative immunohistochemical studies of
bcl-2 and p53 proteins in benign and malignant ovarian
endometriotic cysts. Cancer. 94:2935–2940. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nomura H, Tamada Y, Miyagi T, et al:
Expression of NEU3 (plasma membrane-associated sialidase) in clear
cell adenocarcinoma of the ovary: Its relationship with T factor of
pTNM classification. Oncol Res. 16:289–297. 2006.PubMed/NCBI
|
|
41
|
Sönmez H, Süer S, Güngör Z, Baloglu H and
Kökoglu E: Tissue and serum sialidase levels in breast cancer.
Cancer Lett. 136:75–78. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spowart JE, Townsend KN, Huwait H, et al:
The Autophagy Protein LC3A Correlates with Hypoxia and is a
Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer.
J Pathol. 228:437–447. 2012.PubMed/NCBI
|
|
43
|
Cuff J, Salari K, Clarke N, Esheba GE,
Forster AD, Huang S, West RB, Higgins JP, Longacre TA and Pollack
JR: Integrative bioinformatics links HNF1B with clear cell
carcinoma and tumor-associated thrombosis. PLoS One. 8:e745622013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kato M, Yamamoto S, Takano M, Matsubara O
and Furuya K: Aberrant expression of the mammalian target of
rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1
in the development of ovarian clear-cell adenocarcinoma. Int J
Gynecol Pathol. 31:2542–63. 2012. View Article : Google Scholar
|
|
45
|
Mahata P: Biomarkers for epithelial
ovarian cancers. Genome Inform. 17:184–193. 2006.PubMed/NCBI
|
|
46
|
Lin F, Shi J, Liu H, et al:
Immunohistochemical detection of the von Hippel-Lindau gene product
(pVHL) in human tissues and tumors: A useful marker for metastatic
renal cell carcinoma and clear cell carcinoma of the ovary and
uterus. Am J Clin Pathol. 129:592–605. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mehla K and Singh PK: MUC1: A novel
metabolic master regulator. Biochim Biophys Acta. 1845:126–135.
2014.PubMed/NCBI
|
|
48
|
Li B, Jin H, Yu Y, et al: HOXA10 is
overexpressed in human ovarian clear cell adenocarcinoma and
correlates with poor survival. Int J Gynecol Cancer. 19:1347–1352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miyamoto M, Takano M, Iwaya K, et al:
X-chromosome-linked inhibitor of apoptosis as a key factor for
chemoresistance in clear cell carcinoma of the ovary. Br J Cancer.
110:2881–2886. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Skirnisdottir I, Bjersand K, Akerud H and
Seidal T: Napsin A as a marker of clear cell ovarian carcinoma. BMC
Cancer. 13:5242013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang L, Siu MK, Wong OG, et al: iASPP and
chemoresistance in ovarian cancers: Effects on paclitaxel-mediated
mitotic catastrophe. Clin Cancer Res. 17:6924–6933. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Maeda D, Ota S, Takazawa Y, et al:
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
Mod Pathol. 22:824–832. 2009.PubMed/NCBI
|
|
53
|
Suzuki S, Yoshikawa T, Hirosawa T, et al:
Glypican-3 could be an effective target for immunotherapy combined
with chemotherapy against ovarian clear cell carcinoma. Cancer Sci.
102:1622–1629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tsuda H, Ito YM, Ohashi Y, et al:
Identification of overexpression and amplification of ABCF2 in
clear cell ovarian adenocarcinomas by cDNA microarray analyses.
Clin Cancer Res. 11:6880–6888. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee HJ, Do JH, Bae S, et al:
Immunohistochemical evidence for the over-expression of Glutathione
peroxidase 3 in clear cell type ovarian adenocarcinoma. Med Oncol.
28:(Suppl 1). S522–S527. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Miao Y, Cai B, Liu L, Yang Y and Wan X:
Annexin IV is differentially expressed in clear cell carcinoma of
the ovary. Int J Gynecol Cancer. 19:1545–1549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kuroda T, Hirohashi Y, Torigoe T, et al:
ALDH1-high ovarian cancer stem-like cells can be isolated from
serous and clear cell adenocarcinoma cells, and ALDH1 high
expression is associated with poor prognosis. PLoS One.
8:e651582013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kato N, Toukairin M, Asanuma I and
Motoyama T: Immunocytochemistry for hepatocyte nuclear factor-1beta
(HNF-1beta): A marker for ovarian clear cell carcinoma. Diagn
Cytopathol. 35:193–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Arakawa N, Miyagi E, Nomura A, et al:
Secretome-based identification of TFPI2, a novel serum biomarker
for detection of ovarian clear cell adenocarcinoma. J Proteome Res.
12:4340–4350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Abu Saadeh F, Norris L, O'Toole S, et al:
Tumour expresion of tissue factor and tissue factor pathway
inhibitor in ovarian cancer-relationship with venous thrombosis
risk. Thromb Res. 132:627–634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yamamoto S, Konishi I, Mandai M, et al:
Expression of vascular endothelial growth factor (VEGF) in
epithelial ovarian neoplasms: Correlation with clinicopathology and
patient survival, and analysis of serum VEGF levels. Br J Cancer.
76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yoffou PH, Edjekouane L, Meunier L, et al:
Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in
epithelial ovarian cancer. PLoS One. 6:e207052011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Quattrocchi L, Sisson M, Green A, Martin
SG, Durrant L and Deen S: Expression of angiogenic chemokines in
ovarian clear cell carcinoma. J Obstet Gynaecol Res. 39:297–304.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Suh EJ, Kabir MH, Kang UB, et al:
Comparative profiling of plasma proteome from breast cancer
patients reveals thrombospondin-1 and BRWD3 as serological
biomarkers. Exp Mol Med. 44:36–44. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sundar IK, Yao H and Rahman I: Oxidative
stress and chromatin remodeling in chronic obstructive pulmonary
disease and smoking-related diseases. Antioxid Redox Signal.
18:1956–1971. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Samartzis EP, Noske A, Dedes KJ, Fink D
and Imesch P: ARID1A mutations and PI3K/AKT pathway alterations in
endometriosis and endometriosis-associated ovarian carcinomas. Int
J Mol Sci. 14:18824–18849. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nishimura S, Tsuda H, Ito K, et al:
Differential expression of hypoxia-inducible protein 2 among
different histological types of epithelial ovarian cancer and in
clear cell adenocarcinomas. Int J Gynecol Cancer. 20:220–226. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Balan V, Wang Y, Nangia-Makker P, et al:
Galectin-3: A possible complementary marker to the PSA blood test.
Oncotarget. 4:542–549. 2013.PubMed/NCBI
|
|
69
|
Ho CM, Lai HC, Huang SH, Chien TY, Lin MC
and Chang SF: Promoter methylation of sFRP5 in patients with
ovarian clear cell adenocarcinoma. Eur J Clin Invest. 40:310–318.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Saeki H, Hashizume A, Izumi H, et al: The
utility of serum N-ERC/mesothelin as a biomarker of ovarian
carcinoma. Oncol Lett. 4:637–641. 2012.PubMed/NCBI
|
|
71
|
Ho CM, Cheng WF, Lin MC, et al: Prognostic
and predictive values of E-cadherin for patients of ovarian clear
cell adenocarcinoma. Int J Gynecol Cancer. 20:1490–1497.
2010.PubMed/NCBI
|
|
72
|
Kusumoto T, Kodama J, Seki N, Nakamura K,
Hongo A and Hiramatsu Y: Clinical significance of syndecan-1 and
versican expression in human epithelial ovarian cancer. Oncol Rep.
23:917–925. 2010.PubMed/NCBI
|
|
73
|
Yamaguchi K, Mandai M, Oura T, et al:
Identification of an ovarian clear cell carcinoma gene signature
that reflects inherent disease biology and the carcinogenic
processes. Oncogene. 29:1741–1752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kato N, Sasou S, Teshima S and Motoyama T:
Overexpression of laminin-5 gamma2 chain in clear cell carcinoma of
the ovary. Virchows Arch. 450:273–278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Akahane T, Sekizawa A, Okuda T, Kushima M,
Saito H and Okai T: Disappearance of steroid hormone dependency
during malignant transformation of ovarian clear cell cancer. Int J
Gynecol Pathol. 24:369–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Oe S, Hasegawa K, Nagase S, Kato R, Torii
Y and Udagawa Y: Expression of podoplanin in epithelial ovarian
carcinomas and its potential as a marker for clear cell
adenocarcinoma. Int J Gynecol Pathol. 29:405–410. 2010. View Article : Google Scholar : PubMed/NCBI
|
